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Abstract: Myelodysplastic syndromes (MDS) are a varied group of diseases leading to 
  significant morbidity and mortality. Therapy of MDS has been difficult, with supportive cares 
used to ameliorate symptoms, and hematopoietic stem cell transplantation the only curative 
option. Agents, such as the cytidine analog azacitidine, exert an effect on DNA methyltransferase 
leading to a reduction in DNA methylation, a process thought to be key to the pathogenesis of 
MDS. Recently, azacitidine has been shown to prolong survival and improve quality of life in 
patients with MDS, while maintaining a favorable adverse effect profile. This review highlights 
the scientific rationale for the use of azacitidine in addition to its application in current clinical 
practice for patients with MDS.
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Introduction
Myelodysplastic syndromes (MDS) are a complex and heterogeneous group of clonal 
stem cell disorders manifested by diverse clinical and biologic paths with varying 
need for transfusions, risk of infection, and risk of progression to acute leukemia. 
The US Food and Drug Administration (FDA) approval of 3 new therapeutic agents 
for MDS over the last few years (azacitidine, lenalidomide, and decitabine), as well 
as innumerable available clinical trials, has changed the treatment paradigm for this 
spectrum of diseases; however, stem cell transplantation remains the only curative 
therapy for MDS.
MDS pathophysiology is complex, diverse, and still not completely understood. 
Structural alterations in DNA, as evident by the cytogenetic abnormalities seen 
in a majority of patients, play a role in the pathogenesis of disease due to loss or 
alteration of genetic material involved in proliferation, differentiation, or apoptosis. 
  Epigenetic changes in the form of modifications to the transcriptional capacity of the 
cell via processes, such as DNA methylation or histone acetylation, can also alter 
gene expression impacting disease biology.1 As such, DNA hypermethylation of key 
cellular machinery involved in cell cycle regulation, apoptosis, and tumor suppressor 
control is well documented in the pathogenesis of MDS, as well as in other cancers. 
The tumor suppressor and cell cycle regulatory gene p15INK4B is an example of one 
important gene noted to be hypermethylated in MDS resulting in uncontrolled cell 
cycle progression and cellular proliferation.1–6
Hypermethylated DNA sequences of key cellular machinery provide a biologically 
rational therapeutic target for MDS. Currently, both FDA-approved hypomethylating 
agents (azacitidine and decitabine) have shown good clinical responses in patients OncoTargets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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with MDS with recent data confirming an overall survival 
(OS) benefit with azacitidine therapy.7–11 This review will 
highlight azacitidine pharmacology, explore azacitidine 
efficacy studies both as single-agent therapy and in com-
bination with other drugs, compare available data between 
azacitidine and decitabine, address the impact on patient 
quality of life (QOL), and discuss the role of azacitidine in 
the comprehensive care of patients with MDS.
Pharmacology
Mechanism of action
Azacitidine (5-azacytidine; Vidaza; Celgene Corporation, 
Summit, NJ, USA) was the first drug approved for the 
treatment of MDS by the FDA.12 Azacitidine is an analog 
of cytidine, a pyrimidine nucleoside that is a component of 
human RNA. Although azacitidine falls into the category of 
hypomethylating agents, its mechanism of action is likely 
multifactorial.
The effectiveness of azacitidine is contingent on its 
entry into cells via nucleoside transporter proteins. The 
specific protein responsible for azacitidine transport 
remains unclear.13 After multiple phosphorylation steps, 
azacitidine is largely (∼80%) incorporated into RNA, where 
it potentially exerts a cytotoxic effect by inhibiting protein 
translation.13,14 Whether or not azacitidine plays a role in RNA 
hypomethylation has yet to be determined.14 Ribonucleotide 
reductase converts a portion (∼10%–20%) of phosphorylated 
  azacitidine to 5-aza-dCDP, a phosphorylated metabolite 
of 5-aza-2′-deoxycytidine (decitabine; Dacogen; Eisai 
  Incorporated, Woodcliff Lake, NJ, USA). The compound 
5-aza-dCDP is further phosphorylated and incorporated into 
DNA as azacytosine.14
In the environment of malignancy, DNA   methyltransferase 
(DNMT) has been known to hypermethylate cytosine 
  residues at cytosine–guanine repeat sequences (CpG 
islands).15 The incorporation of azacytosine into DNA leads 
to inhibition of DNMT.16 DNMT recognizes the modified 
  azacytosine–guanine regions as native CpG islands and 
in turn forms a covalent complex with the abnormal 
  dinucleotide regions.13 It is believed that DNMT becomes 
“trapped”, which   eventually leads to its degradation and sub-
sequent inability to   hypermethylate CpG islands.17 Through 
this process, subsequent DNA copies are able to propagate 
without the potential harmful effects of hypermethylation.15 
By reducing the quantity of hypermethylated DNA produced, 
azacitidine can serve to limit the proliferation of malignant 
cells, while allowing an increased proportion of normal 
cells to   differentiate. Interestingly, methylation reversal 
has not been shown to consistently correlate with clinical 
response   highlighting our incomplete understanding of the 
full   spectrum of   hypomethylating agent activity.18,19 Although 
there is some suggestion that DNA methylation may be pre-
dictive of outcomes for patients with MDS, currently there 
is no standard role for clinically monitoring methylation in 
patients treated with hypomethylating agents.20
In the 1960s–1980s, azacitidine was studied in a 
  variety of malignancies, focusing primarily on hematologic 
  malignancies. When used at high doses (150–400 mg/m2), 
in initial studies, azacitidine predominantly exhibited direct 
  cytotoxicity. Unfortunately, in that manner, its use was limited 
by significant toxicities and was only variably effective.21–24 
With greater mechanistic understanding of azacitidine’s 
potential hypomethylating effects, the variable efficacy with 
high-dose therapy is understandable given the need for cellular 
survival to produce hypomethylated progenitor DNA.
Dosing
The FDA-approved dosing scheme for azacitidine is outlined 
in the FDA approval summary.25 Azacitidine is approved for 
patients with MDS. The starting dose has been recommended 
at 75 mg/m2 administered either subcutaneously (SQ) or 
intravenously (IV) for 7 straight days out of a 28-day cycle. 
The dose can be increased to 100 mg/m2 if there is no effect 
and no dose-limiting toxicity after 2 cycles. Administration 
of azacitidine is recommended to continue as long as there 
is a clinical benefit in the absence of dose-limiting toxicities. 
There are no first-cycle dose adjustments currently recom-
mended regardless of the patient’s peripheral blood counts 
or renal function given the nature of the cytopenias inherent 
in MDS. Adjustments may be made for subsequent cycles 
based on hematologic status, alteration in renal function, or 
change in serum bicarbonate levels. It is important to note 
that azacitidine is contraindicated in patients with diffuse 
hepatic metastases.25
A recent trial suggested that SQ azacitidine administered 
over 5 consecutive days (75 mg/m2/d), 5 consecutive days 
with 2 days off followed by 2 more days of   administration 
(75 mg/m2/d), or 5 consecutive days with 2 days off   followed 
by 5 more days of administration (50 mg/m2/d) may be 
  reasonable dosing alternatives for those patients in the lower 
risk MDS International Prognostic Scoring System (IPSS) 
categories of low/INT-1 (intermediate-1) with reported 
responses demonstrating transfusion independence and 
hematologic improvement (HI).26 These alternative dosing 
schedules are not FDA-approved but may offer a greater 
convenience to the patient providing a potentially similar OncoTargets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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benefit to the established dosing regimen in patients whose 
treatment goals are palliative. Studies evaluating the safety 
and efficacy of oral azacitidine are underway and may offer 
even greater convenience to patients in the future.27,28
Pharmacokinetics
Although azacitidine was initially studied with IV delivery, 
it is also approved for SQ injection. Azacitidine has a high 
bioavailability after SQ injection (up to 89% of the equivalent 
IV dose). Peak plasma concentration of azacitidine is reached 
30 minutes after SQ injection, and the plasma half-life of SQ 
azacitidine is 41 minutes. Azacitidine has a large volume of 
distribution, with an apparent preferential uptake in tumor 
tissues although it is unclear how successfully azacitidine can 
cross the blood–brain barrier.29,30 There are data to suggest 
that 5-aza-2′-deoxycytidine (decitabine) can reach measur-
able CSF concentrations in animal models.31 Excretion 
appears to be largely kidney dependent (50%–90%).
Efficacy and safety
Azacitidine as a single agent for MDS
The use of azacitidine was initially investigated in a wide 
variety of clinical scenarios and at generally higher doses than 
currently approved.21–24 In order to limit toxicities and take 
advantage of the recognized mechanism of DNA hypomethy-
lation, azacitidine was further investigated at significantly 
lower doses and primarily in hematologic malignancies.
Silverman and colleagues32 led both laboratory- and 
patient-based investigations into low-dose azacitidine for 
therapy for MDS. Two phase 2 studies through the Cancer 
and Leukemia Group B (CALGB) evaluated azacitidine 
given at 75 mg/m2 IV (CALGB 8421) or SQ (CALGB 8921) 
for 7 consecutive days on a 28-day cycle. Based on updated 
IWG (International Working Group) 2000 response criteria, 
patients receiving IV azacitidine (8421) or SQ azacitidine 
(8921) had responses (combined rates of complete, partial, 
or improved responses) of 44% and 40%, respectively.10,33
The data earning azacitidine its FDA approval was pub-
lished in 2002 by Silverman and colleagues9 and updated in 
2006 with new IWG 2000 response criteria. The CALGB 9221 
study was a phase 3 randomized control trial of low-dose SQ 
azacitidine for patients with MDS. This multi-institutional 
trial included 191 patients randomized to either therapy with 
azacitidine (75 mg/m2 for days 1–7 of a 28-day cycle) or sup-
portive care (transfusions as needed, no hematopoietic growth 
factors). Azacitidine could be increased to 100 mg/m2 after 
2 full cycles if there was no improvement and there were no 
dose-limiting toxicities. The 2 groups were comparable in 
terms of FAB   classifications, IPSS scores, time from diagnosis 
to study entry, and   cytogenetic groupings. In retrospect, a 
central pathology review of marrow specimens determined 
that 19 patients should be classified as acute myeloid leuke-
mia (AML) although this did not ultimately affect the results. 
These patients were excluded from an analysis of progression 
to AML. Importantly, patients in the supportive care arm 
were allowed to cross over to the azacitidine arm after at least 
4 months of supportive care or if they met other criteria for 
worsening disease status prior to that time.9
With outcome data based on the IWG 2000 response 
criteria, of 99 patients in the azacitidine arm, 10% obtained 
complete remission (CR), 1% partial remission (PR), and 36% 
with HI for a total overall response rate (ORR) of 47%.10 The 
supportive care arm (prior to any crossover) showed an ORR 
of 17% with all responses manifest as HI.9 Fifty-one patients 
crossed over from supportive care to azacitidine and obtained 
a CR rate of 6%, PR of 4%, and HI of 25% for an ORR of 
35%.10 Of the 65 patients receiving azacitidine who were red 
blood cell (RBC) transfusion-dependent at the start of the 
trial, 45% became transfusion-independent.9 The   investigators 
noted that most patients who responded did not demonstrate 
this response until 3 or 4 cycles of therapy.9
Within CALGB 9221, treatment with azacitidine was 
shown to prolong time to leukemic transformation or death 
(treatment failure). The mean time to treatment failure 
for patients receiving azacitidine and supportive care was 
21 months and 12 months, respectively (P = 0.007). There 
was a trend toward improved OS in those treated with 
  azacitidine, with a median of 20 months compared with 
14 months for patients in the supportive care arm. Although 
this finding did not reach statistical significance (P = 0.10) 
possibly due to the effect of patient crossover, a subset sur-
vival analysis of patients receiving azacitidine compared 
with patients who either never crossed over or crossed over 
after 6 months of supportive care did reveal a statistically 
significant survival advantage highlighting the impact of 
azacitidine on the natural history of disease and importance 
of use earlier in the patient’s disease course.21 Silverman 
et al9 concluded that the use of azacitidine improved time to 
progression or death, reduced the rate of RBC transfusions, 
and improved measurable hematologic parameters when 
compared with best supportive care (BSC).
The CALGB 9221 trial also evaluated QOL outcomes.34 
Based on QOL questionnaires and telephone surveys, patients 
in the azacitidine group had significantly decreased fatigue 
and dyspnea with improved physical functioning and posi-
tive affect when compared with patients in the supportive OncoTargets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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care arm. Patients who crossed over to azacitidine therapy 
had significant improvements in the same areas. The effects 
seemed most   pronounced in patients who received at least 
4 cycles of azacitidine, which did correlate to the objective 
HIs seen in the outcomes data outlined above. The authors felt 
that these QOL improvements were valid and not explained 
by other effects.34
Based on the promising outcomes from the CALGB 
  azacitidine studies, the International Vidaza High-Risk MDS 
Survival Study Group developed AZA-001, a   multicenter 
phase 3 randomized controlled trial for patients with MDS 
with higher IPSS risk score (intermediate-2/high) random-
izing patients to either azacitidine vs one of 3 conventional 
care regimens (BSC, low-dose cytarabine, or intensive 
chemotherapy).11 Prior to randomization, investigators pre-
selected which conventional care regimen would be the most 
appropriate for a given patient if they were randomized to the 
conventional care arm. They were then randomized either to 
receive SQ azacitidine (75 mg/m2 for days 1–7 of a 28-day 
cycle) or to their designated conventional care   regimen. 
No crossover was allowed in this study, and patients could 
not receive erythropoietin (EPO) analogs. Patients with 
treatment-related MDS were excluded. Patients also had to 
be of good performance status and could not have been previ-
ously treated with azacitidine or have an upcoming planned 
allogeneic hematopoietic stem cell transplant (HCT).11
Of 358 patients, 179 patients were randomized to receive 
azacitidine. For the 179 patients receiving conventional 
care, 105 received BSC, 49 received low-dose cytarabine, 
and 25 received intensive chemotherapy. The outcome 
analysis was based on an intention to treat. Central review 
highlighted a few notable deviations: (1) Eighteen patients 
should have been assigned an IPSS score of INT-1 (5 in the 
azacitidine group and 13 in the conventional care group), 
(2) One-hundred and thirteen of the 358 patients (32%) 
could be diagnosed as AML based on current World Health 
Organization criteria, and 3) Eight patients (4 who received 
azacitidine) went on to receive an unplanned allogeneic 
HCT.11 Of 358 patients, 4 in the azacitidine group and 13 in 
the conventional care group never received therapy but were 
included in the intention-to-treat analysis. For those patients 
treated with azacitidine, the median number of cycles given 
was 9, and 86% of those patients required no azacitidine 
dose adjustments.
The study’s primary end point was OS. Median OS 
was significantly improved (24.5 months vs 15 months) for 
patients receiving azacitidine (P = 0.0001). The Kaplan–Meier 
estimate for 2-year survival for the azacitidine patients was 
significantly improved (50.8% vs 26.2%) over the conven-
tional care regimens (P , 0.0001). This OS benefit persisted 
on analysis of cytogenetic subgroups, including patients with 
abnormalities of chromosome 7.11 OS subgroup analysis 
based on the initial potential conventional care arm assigned 
(BSC only vs low-dose cytarabine vs intensive chemotherapy) 
retained a statistically significant survival benefit in the BSC 
and low-dose cytarabine groups.   However, for patients initially 
potentially designated for intensive chemotherapy if random-
ized to the conventional care arm, the use of azacitidine 
resulted in an improved median OS of 25.1 months vs 15.7 
months for those patients who did receive intensive that did 
not reach statistical significance. (P = 0.51). The lack of sta-
tistical significance is likely due to the relatively low number 
of patients in this designated group (total of 42).23
In the entire cohort of patients, the time to   transformation 
to AML (defined in the study as bone marrow blast   percentage 
of .30%) was delayed to 17.8 months for those receiving 
azacitidine vs 11.5 months for those in the conventional 
care arm (P , 0.00001). Subgroup analysis, based on the 
original potential preselected conventional care arm, revealed 
a significant improvement in time to leukemia progression 
in the azacitidine vs BSC arm (15 months vs 10.1 months). 
However, the trend didn’t reach significance in those patients 
treated with azacitidine vs low-dose cytarabine or intensive 
chemotherapy.11
AZA-001 trial was the first to prospectively confirm 
azacitidine’s impact on OS in high-risk de novo patients 
with MDS. Subsequent meta-analysis reviewing 4 large 
hypomethylation MDS trials confirmed the OS benefit with 
azacitidine therapy.35 Future study including patients with 
treatment-related MDS are warranted to determine if this 
survival benefit also applies to that patient population.
Azacitidine in combination with other agents
Currently, there are no FDA-approved regimens that include 
azacitidine in combination with other drugs for therapy of MDS. 
Several studies have evaluated azacitidine in   combination 
with other cytotoxic agents or with other epigenetic-  derived 
therapy, such as histone deacetylase inhibitors. A large, mul-
ticenter, phase 3 ECOG study evaluating the combination of 
azacitidine with MS-275, a histone deacetylase inhibitor, is 
currently underway based on promising phase 1 combination 
data. Azacitidine in combination with sodium phenylbu-
tyrate, with valproic acid alone, with all-trans retinoic acid, 
hydroxyurea, and gemtuzumab ozogamicin, and with thalido-
mide has also been evaluated in early-phase studies.36–40 The 
majority of these studies have included patients with either OncoTargets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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high-risk MDS or AML progressing on standard therapies. 
Generally, the   combinations have been deemed safe and have 
shown some clinical responses.36–40
Recent phase 1 data using the combination of azacitidine 
and lenalidomide in patients with high-risk MDS has shown 
promising results. Six dosing schedules were assessed with 
a maximum tolerated dose not found. The combination was 
found to be safe and tolerable, and the CR rate of 44% is 
slightly higher than outcomes of each individual single-
drug study alone. Future phase 2 testing is underway with 
a dosing schedule of azacitidine 75 mg/m2 on days 1–5 and 
lenalidomide 10 mg daily on days 1–21 to determine if the 
combination provides improved responses compared with 
either azacitidine or lenalidomide alone.41
Azacitidine prior to HCT
Randomized trials evaluating the safety or efficacy of azaciti-
dine administration prior to HCT are currently lacking. Use 
of both azacitidine and decitabine prior to allogeneic stem 
cell transplantation with either sibling or matched unrelated 
donors have been reported without increasing transplant-
related toxicity.42,43 However, the impact of pretransplant 
hypomethylating therapy on posttransplant outcomes, such 
as incidence of relapse, OS, and disease-free survival, is 
unknown. Recent data indicate that azacitidine may have an 
immune-modulating effect on T cells, with potential implica-
tions on graft-vs-host disease in the transplant setting; thus, 
further investigation is warranted.44
Safety and tolerability
In early trials, higher IV doses (100–400 mg/m2) of azacitidine 
were associated with significant nausea, vomiting, infusion 
reactions, in addition to severe hematologic toxicities.21–24 
Additionally, in previous studies evaluating azacitidine in 
patients with metastatic tumors or with concurrent cirrhosis, 
severe hepatic toxicity was seen. As a result, azacitidine is 
contraindicated in patients with significant hepatic involve-
ment by malignancy.12,30
With current dosing schemes, azacitidine is   generally 
well-tolerated. Interestingly, a stringent evaluation of adverse 
effects is made difficult by similar adverse events reported 
in both patients receiving azacitidine and those patients in 
  supportive care arms who suffered from sequelae due to the 
natural history of their MDS.30 The documented adverse effects 
are primarily hematologic. Patients   receiving   azacitidine on 
the AZA-001 trial frequently experienced grade 3 or 4 neu-
tropenia (91%), thrombocytopenia (85%), or anemia (57%) 
during their course of care compared with the patients in 
conventional care arms at 76%, 80%, and 68%, respectively.11 
Given the inherent biology of MDS,   attribution of cytopenias 
to azacitidine vs MDS itself is   challenging. Patients treated 
with azacitidine generally do have an increase in transfusion 
requirements during their first cycles of therapy, although this 
effect disappears in those with a positive response to therapy.9 
In addition, the important effect noted in the AZA-001 trial 
was that azacitidine therapy did not result in an increased 
risk of infection.11 For patients who discontinued therapy 
early due to adverse effects, the reason was generally due to 
hematologic toxicities.10,11,30 Additionally, in CALGB studies, 
there was no increased risk of bleeding events in patients on 
azacitidine.10 In summary, cytopenias inherent to both therapy 
and MDS did not lead to increased risk of bleeding or infec-
tion in those patients treated with azacitidine, and for those 
who responded to therapy, resolution of cytopenias occurred 
with a median time to response of 3 months.
Certain nonhematologic toxicities commonly   documented 
in patients receiving azacitidine included nausea,   vomiting, 
constipation, diarrhea, anorexia, fatigue, arthralgias, head-
ache, hepatic function abnormalities, and injection site 
reactions (with anecdotal reports suggesting primrose oil 
to ameliorate the SQ injection site reactions).10,11,30,45 Also, 
adverse effects are more frequently reported within the initial 
2 cycles of therapy.30 Although nausea and vomiting were 
a dose-limiting toxicity in the 1960s–1980s, presumably 
modern-day antiemetic therapy has played a role in improv-
ing the tolerability of azacitidine.
Patient perspectives in MDS and azacitidine
Problems stemming from the ineffective hematopoiesis 
hallmark to MDS greatly impacts patient’s QOL. Due to the 
subjective impact of disease burden on QOL,   health-related 
quality-of-life assessment tools have been developed to 
objectively evaluate the impact of disease and treatment on 
patient’s overall life satisfaction. Numerous tools exist with 
the Functional Assessment of Cancer Therapy (FACT) based 
evaluations and the European Organization for Research 
and Treatment of Cancer (EORTC) Core Quality of Life 
Questionnaire (QLQ-C30), the tools most frequently cited. 
Although an exhaustive review on QOL in MDS is beyond 
the scope of this review, a recent publication by Pinchon et al46 
summarizes the available QOL data based on impact of 
RBC transfusions and symptoms associated with anemia 
on patients with MDS. Most notable, the   findings suggest 
that generally patients whose hemoglobin level rises and 
transfusion requirements decrease have improved QOL. 
These results were evident in those treated solely with growth OncoTargets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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factor support (EPO and darbepoetin alfa with or without 
granulocyte-colony-stimulating factor), as well as in those 
treated with hypomethylating agents.7,34,47–52 Other QOL tools 
have identified the important impact of fatigue on daily func-
tion and ability to work or do desired activities. Additional 
factors, such as fever, infections, weight loss, and bleeding, 
impacted QOL to a lesser degree.53 These data clearly dem-
onstrate the dramatic impact of MDS-related complications 
on patient’s QOL.
Based on azacitidine’s efficacy via improved blood 
counts, transfusion independence, remissions, prolonged 
OS, and delayed time to leukemic transformation, a   positive 
impact on QOL is expected. QOL assessments were a key 
component to the outcomes assessed in CALGB 9221 
  randomizing patients to azacitidine vs BSC and confirmed 
this impact. Specifically, patients in the azacitidine arm 
noted significant improvements in fatigue, physical function, 
dyspnea, psychosocial distress, and affect.9,34
Although azacitidine is filled with promise of   potential clin-
ical benefits, the therapy is not without possible   complications 
and frustrations. As with any chemotherapy, initial treatment 
is associated with worsening of baseline cytopenias and an 
expected increased rate of   transfusions until a response is 
manifest. However, based on the   mechanism of action and 
expected slower onset of response, patience and perseverance 
to continue therapy are required for sometimes a prolonged 
period of time before seeing a clinical benefit. With a median 
time to response of 3 cycles translating into 80+ days, adher-
ence to therapy by both patient and physician for a minimum 
of 4 cycles is crucial to allow enough time to until response 
assessment.10
Additional therapeutic options in MDS
Decitabine
Decitabine (5-aza-2′-deoxycytidine) is a cytosine analog that, 
through a series of metabolic steps differing from azacitidine, 
eventually incorporates into DNA.14 At low doses, decitabine 
can lead to DNMT degradation and subsequent hypomethyla-
tion, whereas higher doses lead to direct cytotoxicity.14 Initial 
studies using a dosing schedule of 15 mg/m2 IV over 3 hours 
every 8 hours for a total of 3 days repeated every 6 weeks 
yielded an ORR of 17% with a CR rate of 9%.7 Subsequent 
studies using alternative dosing regimens more appropriate 
for outpatient use (20 mg/m2 days 1–5 SQ, 20 mg/m2 days 
1–5 IV , and 10 mg/m2 IV days 1–10) produced higher CR 
rates and ORRs. The dosing schedule of 20 mg/m2 IV days 
1–5 yielded the highest CR rates (39%) along with evidence 
of p15Ink4B hypomethylation in those achieving a CR.8 Given 
these good responses, the above dosing schedule is the one 
most frequently used in practice.
Recent meta-analysis of 4 significant azacitidine and 
  decitabine trials confirmed that hypomethylating agents 
improve survival compared with BSC (hazard ratio 
[HR] = 0.66; 95% confidence interval [CI], 0.55–0.8), 
  prolong time to AML transformation or death (HR = 0.69; 
95% CI, 0.58–0.82), and improved CR (HR = 7.63; 95% 
CI, 1.41–41.17), PR (HR = 6.01; 95% CI, 2.93–12.31), 
and HI rates (HR = 3.06; 95% CI, 1.09–8.6). Interestingly, 
freedom from RBC transfusions was not improved with 
  hypomethylating agents compared with conventional care 
(HR = 10.65; 95% CI, 0.29–388.92). Hypomethylating 
agents were, as expected from individual trial data, associ-
ated with cytopenias and associated febrile neutropenia 
and a higher treatment-related mortality compared with 
conventional care.35
Independent analysis of both azacitidine and   decitabine 
with respect to OS and time to AML/death revealed an 
  advantage seen only with azacitidine (OS: azacitidine 
[HR = 0.56; 95% CI, 0.44–0.73] vs decitabine [HR = 0.88, 
95% CI, 0.66–1.17]) (time to AML/death: azacitidine 
[HR = 0.54; 95% CI, 0.42–0.71] vs decitabine [HR = 0.85; 
95% CI, 0.66–1.07). Although both drugs show   encouraging 
clinical responses, the OS and delayed time to AML benefit 
seen only with   azacitidine trials are interesting. The   studies 
analyzed had similar proportion of IPSS risk groups/FAB 
Table 1 Treatment approach in nontransplant candidates at the 
University of Minnesota
iNT-1/low-risk 
iPSS
No treatment indicated → supportive measures only
• Symptomatic anemia
    if anemic + low ePO level: trial of ePO 
supplementation with or without G-CSF
•   Transfusion-dependent anemia not responding  
to growth factors
  5q−: lenalidomide 
    Normal/other cytogenetics: order of treatment  
choice
  1) Azacitidine
  2) Clinical trial
  3)   ATG/CSA: if younger (,60 years) or HLA DR15
• Neutropenic or thrombocytopenic requiring therapy
  1) Azacitidine
  2) Clinical trial if not responding to azacitidine
iNT-2/high-risk 
iPSS 
• Requiring therapy
  Azacitidine
• Clinical trial if progression on azacitidine
Abbreviations: ePO, erythropoietin; G-CSF, granulocyte-colony-stimulating factor; 
ATG,  antithymocyte  globulin;  CSA,  cyclosporine;  HLA-DR15,  human  leukocyte 
antigen DR-15.OncoTargets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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(French American British) groups and similar median ages; 
however, the duration of decitabine therapy was slightly lower 
with a median of 3–4 cycles vs 9 cycles with azacitidine.35 
The differing   treatment exposure may explain the differing 
impact on OS benefit; however, only randomized studies 
  comparing azacitidine and decitabine will answer the question 
of equivalence or superiority. Both agents produce desirable 
clinical responses and are reasonable therapeutic tools, but 
given the documented benefits of improved OS and delayed 
time to AML in the current literature, azacitidine has a mild 
advantage. Limited data does suggest clinical activity of 
decitabine in those patients with MDS whose disease stopped 
responding to azacitidine (ORR 28%) possibly suggesting 
some additional mechanisms of action and the importance 
of both hypomethylating agents in MDS.54
Current clinical investigations
Numerous clinical trials evaluating novel therapeutic   combinations 
for MDS are currently open and   recruiting, although active stud-
ies are primarily limited to phase 1/2   investigations. Of interest 
are several studies using azacitidine or decitabine in combina-
tion with various histone deacetylase inhibitors (vorinostat, 
panobinostat, and   entinostat) potentially enhancing current 
epigenetic-based therapy. Azacitidine is also being studied in 
combination with agents, such as lenalidomide and bortezomib. 
Studies evaluating azacitidine in oral form, hypomethylating 
agents prior to allogeneic stem cell transplantation or in the 
role of maintenance therapy for MDS treated with intensive 
chemotherapy, are ongoing. A community-based, phase 4 trial of 
azacitidine vs decitabine has recently started recruiting.55
In small studies, a number of additional agents have docu-
mented clinical activity in MDS. Specifically, clofarabine, which 
has shown promise in older, newly diagnosed, and relapsed 
refractory patients with AML, has been tested in the oral form 
in patients with MDS yielding a 25% complete response rate.56–58 
Combinations of antithymocyte globulin and etanercept have 
also shown evidence of HI with ORRs of approximately 56% 
in small-scale studies.59 Studies involving bortezomib, arsenic 
trioxide, tipifarnib, a farnesyl-transferase inhibitor, and tyrosine 
kinase inhibitor, dasatinib, and many others are ongoing.55
Conclusion
Therapeutic options for the MDS have improved significantly over 
the last decade. However, given the variability in natural history of 
Table 2 Treatment approach in transplant candidates at the University of Minnesota
Low-risk iPSS Supportive care as above
Due to potential long natural history, transplant typically not indicated up front, even in young patients, unless 
showing evidence of progression
    Note: Patients with transfusion dependency not responding to therapy (growth factors, hypomethylating agents, 
etc) should be transplanted earlier despite their low-risk iPSS score due to higher TRM noted with higher 
pretransplant ferritin levels and transfusion dependence
iNT-1 iPSS Age $50 years: Poorer outcomes compared with younger patients. Thus, consideration of transplantation at diagnosis
  if ,5% blasts in marrow at diagnosis: Transplant with no up front therapy
  if .5% blasts in marrow at diagnosis: initiate therapy to reduce blast percentage and proceed to transplant
    Therapy choice
      Azacitidine: 1st choice if have time to achieve benefit
      AML type induction chemotherapy: if high proliferative capacity and need urgent response
if age ,50 years: May have prolonged natural history without significant intervention, so no transplant up front unless 
failure of below interventions or progressive cytopenias/disease progression
  Supportive care if minimal cytopenias
  Thrombocytopenic/neutropenic requiring treatment:
    Azacitidine
  Symptomatic anemia requiring transfusions
    5q−: patients: Lenalidomide
    Normal/other cytogenetics: Azacitidine
if progressed through above therapies and need further disease reduction prior to transplantation → clinical trial
iNT-2/high-risk  
iPSS/t-MDS
All age patients (,70–75 years)
Prepare for allogeneic HCT from diagnosis: HLA type patient, sibs, initiate MUD/cord search if no sibling match
Treatment, as needed, to reach goal of ,5% blasts
  Azacitidine 1st choice: (needs 3 to 4 cycles to assess true response)
  induction chemotherapy if high proliferative rate
Clinical trial if suboptimal response to above and need further disease reduction pretransplant
Abbreviations: TRM, treatment-related mortality; AML, acute myeloid leukemia; t-MDS, treatment-related MDS; HCT, hematopoietic stem cell transplant; HLA, human 
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disease, the variety of treatment options, and the potential morbid-
ity and mortality of specific therapies, MDS treatment decision-
making is challenging with respect to timing of therapy initiation, 
therapeutic agent choice, and timing of transplant, if planned. 
Our treatment approach at the University of Minnesota has based 
decision-making on diagnostic IPSS score, WPSS (WHO-based 
Prognostic Scoring System) score, cytogenetics, lineages impacted, 
and transplant candidacy and is summarized in Tables 1 and 2.
Hypomethylating agents (azacitidine and decitabine) 
are integral to the current management of patients with 
MDS.35,60,61 When using these agents, it is important to 
remember that a minimum of 4 cycles should be given, in 
the absence of toxicity or rapidly progressive disease, to 
allow for adequate chance for response. Once a response is 
achieved, therapy should be continued until disease progres-
sion or treatment-related toxicity precludes further therapy. 
Hypomethylating agents may be effective therapy in addi-
tional roles, such as maintenance therapy after induction 
chemotherapy or up front therapy for elderly patients with 
AML not proceeding to transplant, maintenance therapy 
after allogeneic stem cell transplantation for MDS attempt-
ing to reduce risk of relapse, or combined with other agents 
for patients with MDS unresponsive to standard therapy. 
  Clinical trials are underway assessing the efficacy of azac-
itidine and decitabine within these clinical contexts.
Continued research is crucial to develop new therapies 
for patients with MDS with the hopes of providing curative 
therapeutic alternatives to stem cell transplantation.
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